Objectives: To report the linezolid in vitro activity obtained during the 2015 ZAAPS Program.
Introduction
Linezolid was the first oxazolidinone agent to be approved for clinical use by various national or regional regulatory agencies and is an important therapeutic agent for infections caused by commonly occurring antimicrobial-resistant Gram-positive pathogens. [1] [2] [3] More recently a second oxazolidinone (tedizolid) was approved by the US FDA and the EMA. 4 Oxazolidinone resistance has been detected among clinical isolates, mainly among Enterococcus species and the CoNS (Staphylococcus epidermidis and some other species), but the occurrences remain uncommon for Staphylococcus aureus, CoNS, enterococci, including VRE and streptococci in large surveillance programmes. 1, [5] [6] [7] [8] Alterations of the 23S rRNA and/or L3 and/or L4 ribosomal proteins comprise the most common resistance mechanisms. 1 However, cfr, cfr(B), cfr(C) and optrA represent newer transmissible mechanisms of linezolid resistance. [9] [10] [11] [12] While cfr has been detected in several hosts, including those responsible for outbreaks, [13] [14] [15] [16] [17] optrA was initially reported in enterococcal isolates from human and animal origin in China. 10, 18 Now optrA has been reported from enterococci and Staphylococcus sciuri from other regions. 7, [19] [20] [21] [22] [23] [24] In this ZAAPS (ex-USA) study, the in vitro activity and spectrum of linezolid along with those of clinically available comparator agents are reported. Moreover, further molecular characterization of linezolid resistance mechanisms and epidemiological typing are provided for isolates exhibiting a decreased susceptibility to linezolid (MIC, 4 mg/L).
Materials and methods

Clinical isolates
The ZAAPS Program is part of the SENTRY Antimicrobial Surveillance Program, which monitors antimicrobial resistance and prevalence of pathogens causing bloodstream infections, community-acquired pneumonia, pneumonia in hospitalized patients, skin and skin structure infections, urinary tract infections and intraabdominal infections (six main study protocols). Participating sites followed instructions specific for each of these protocols to select and include consecutive and unique (one per patient) isolates that were deemed clinically relevant based on local criteria until they reached a target number of 250-500 pathogens per site (depending on hospital size). For the ZAAPS study, staphylococci, enterococci and streptococci were selected (a total of 7587 isolates). These isolates were recovered from 65 medical centres distributed on five continents (32 countries) from January to December 2015 ( Table 1) .
Isolates that met the selection criteria for each of the specific protocols were initially identified by the participant laboratory using local practices and submitted to the coordinating monitoring laboratory (JMI Laboratories, North Liberty, IA, USA). Those isolates showing questionable phenotypic and/or biochemical results had the identification confirmed by MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). All streptococci were subjected to MALDI-TOF MS.
Antimicrobial susceptibility testing
Isolates were tested for susceptibility by broth microdilution using 96-well panels following the CLSI guidelines. 25 MIC testing was performed using frozen-form panels manufactured by JMI Laboratories containing CAMHB (2.5%-5% lysed horse blood added for testing streptococci). Isolates exhibiting initial linezolid MIC results of 4 mg/L were re-tested in a frozen-form panel containing an extended linezolid dilution range (1-128 mg/L). Bacterial inoculum density was monitored by colony counts to ensure an adequate number of cells for each testing event. MIC values were validated by concurrently testing CLSI-recommended quality control reference strains (S. aureus ATCC 29213, Enterococcus faecalis ATCC 29212 and Streptococcus pneumoniae ATCC 49619).
26 MIC interpretations were based on the CLSI and EUCAST breakpoint criteria, except for tigecycline that used FDA-approved criteria.
26-28
Detection of linezolid resistance mechanisms and epidemiology typing
Isolates that showed elevated MIC results for linezolid (MIC, 4 mg/L) were selected for further characterization at the central laboratory. The presence of cfr, cfr(B) and mutations in the 23S rRNA and ribosomal proteins (L3 and L4) were investigated by PCR and sequencing of amplicons on both strands, as previously described. 9 In addition, isolates were screened for the newly described optrA gene. 10 Where applicable, isolates that met the screening criteria (i.e. linezolid MIC 4 mg/L) were subjected to MLST as described elsewhere, 29 and those isolates of the same species recovered from the same medical site were subjected to PFGE.
Results and discussion
Linezolid inhibited .99.9% of S. aureus at 2 mg/L, with MIC 50 results of 1 mg/L, regardless of methicillin (oxacillin) phenotype (Tables 2 and 3) . A similar MIC 50 result (0.5 mg/L) for linezolid was observed for CoNS, with the vast majority of isolates (99.7%) inhibited at 2 mg/L ( Table 2 ). Non-susceptible results for linezolid (MIC, .4 mg/L) were observed for one isolate of S. aureus (ST7) from Poland and three isolates of CoNS from Italy. These isolates had alterations in the 23S rRNA and/or L3/L4 ribosomal proteins, and one isolate of S. epidermidis harboured the cfr resistance gene ( Table 4 ). The three S. epidermidis isolates were from Italy, two from Genoa and one from Milan. One isolate from Genoa harboured G2576T and L3 mutations in addition to cfr (linezolid MIC, 64 mg/L), and this isolate showed a PFGE profile, SEPI175A (ST2), observed previously at that institution in 2008, 2010 and 2013. 1, 5, 30 ST2 isolates were associated with the dissemination and establishment of a linezolid-resistant S. epidermidis clone in a regional hospital in Ancona, Italy 31 and other hospitals. 32 The other S. epidermidis isolate from Genoa harboured L3 and L4 mutations (linezolid MIC, 16 mg/L). The PFGE profile of that isolate, SEPI175C (ST5), matched an isolate observed in 2007 at that site. An ST5 linezolid-resistant S. epidermidis isolate was also recently Pfaller et al.
recovered from Ancona, Italy in 2015 and demonstrated similar alterations in L3 and L4. 31 The resistant S. epidermidis isolate from Milan (ST5) harboured a G2576T and L3 mutation (linezolid MIC, 32 mg/L). Other ST types, such as ST23 and ST83 have been associated with linezolid resistance in several hospitals in Italy. 29, [31] [32] [33] In addition, S. epidermidis isolates associated with ST22 and disseminated in Greece were determined to show a phenotype of linezolid dependence 34 ; however, such isolates were not observed in this country during this study, although a single site in Athens participated with 149 isolates (all linezolid susceptible; Table 1 ) and only three S. epidermidis (data not shown).
Comparative analysis showed that linezolid and vancomycin had similar MIC 50 and MIC 90 results (MIC 50/90 , 1/1 and 0.5/1 mg/L for linezolid and vancomycin, respectively) for the overall collection of S. aureus, with equivalent results among isolates from North America (Canada only), Latin America, Europe and Asia-Pacific (APAC) regions (data not shown). Similar results were observed for linezolid and vancomycin against the MRSA population (Table 3) . Trimethoprim/sulfamethoxazole [96.7% susceptible (CLSI/EUCAST interpretive criteria)] daptomycin (100.0/100.0% susceptible), tigecycline (100.0/100.0% susceptible) and teicoplanin (100.0/96.9% susceptible) also showed in vitro coverage against MRSA. When tested against CoNS, linezolid (MIC 50/90 , 0.5/1 mg/L; 99.7/99.7% susceptible) had MIC 50 and MIC 90 results 2-fold lower than vancomycin (MIC 50/90 , 1/2 mg/L; 100.0/100.0% susceptible). Moreover, comparable MIC 50 values (0.5 mg/L) were obtained for linezolid against CoNS from each geographical region, as were the values for vancomycin (1 mg/L; data not shown). Other agents tested had more compromised susceptibility rates (33.7%-86.7%), except for teicoplanin, daptomycin and tigecycline (Table 3) .
Overall, linezolid exhibited consistent modal MIC and MIC 50 results (1 mg/L) when tested against enterococci, regardless of species or vancomycin resistance phenotype ( Table 2 ). E. faecalis isolates were generally very susceptible to linezolid, ampicillin, vancomycin, teicoplanin, tigecycline and daptomycin, with equivalent susceptibility (99.0%-100.0%) for all six agents (Table 3) . Enterococcus faecium isolates were largely susceptible to linezolid at 2 mg/L (99.6%) as were VRE species [E. faecalis (five isolates), E. faecium (60 isolates) and Enterococcus gallinarum (one isolate)], among which 78.8% (52 of 66) had a VanA phenotype (Table 2 ). In addition, E. faecium isolates demonstrated an MDR phenotype, and only linezolid, tigecycline and daptomycin had in vitro coverage (Table 3) .
Three enterococci isolates recovered from patients hospitalized in Galway (Ireland), Milan (Italy) and Aveiro (Portugal) exhibited elevated MIC results for linezolid (4-16 mg/L). The linezolidresistant isolate (E. faecalis; ST768) from Galway harboured optrA (MIC, 8 mg/L; Table 4 ). In 2012 and 2014, optrA-containing isolates were observed in Galway, but the isolates exhibited distinct PFGE and MLST patterns. 1, 5, 7 An E. faecium (ST117) from Milan (MIC, 16 mg/L) was observed to harbour G2576T. No mechanism was identified for an Enterococcus hirae from Aveiro, with an MIC of 4 mg/L. No significant changes in the linezolid MIC distributions for enterococci (Table 2) were noted when compared with results reported in previous survey years. For all enterococci tested, linezolid resistance (8 mg/L) was only 0.28% (0.12% in 2014 and 0.13% in 2013). 1, 5, 7, 30 All S. pneumoniae, viridans group streptococci (VGS) and b-haemolytic streptococci (BHS) isolates were inhibited by linezolid at 2, 2 and 1 mg/L, respectively, with equivalent MIC 90 results of 1 mg/L for these groups (Table 2) . Linezolid, levofloxacin, tigecycline and vancomycin were most active (98.6%-100.0% susceptible) against S. pneumoniae (Table 3) . Regional penicillin non-susceptible rates [penicillin MIC, 0.12 mg/L (parenteral meningitis breakpoint)] were: APAC (45.4%); followed by Europe (29.9%); Latin America (26.8%); and Canada (20.0%). Other tested Ex-USA linezolid resistance surveillance agents, including ceftriaxone, showed lower or marginal activity (63.4%-88.5% susceptible) against this species, and only S. pneumoniae isolates from Canada and Latin America showed an acceptable (90%) ceftriaxone susceptibility rate (95.0% and 92.8%, respectively, inhibited at the CLSI/EUCAST meningitis breakpoints). The remaining S. pneumoniae isolates had ceftriaxone susceptibility rates of 77.1% (APAC) and 86.2% (Europe; data not shown). Linezolid, ceftriaxone, clindamycin (EUCAST criteria), levofloxacin, tigecycline and vancomycin overall were active against VGS Ex-USA linezolid resistance surveillance JAC (90.5%-100.0% susceptible) while linezolid, amoxicillin/clavulanic acid, ceftriaxone, penicillin, tigecycline and vancomycin all had 100.0% coverage against BHS (Table 3) . Macrolide resistance was observed in 16.0% of BHS isolates. Constitutive MLS B resistance was 61.5% among erythromycin-resistant isolates, which was higher than observed in 2011 (55.2%), 2012 (48.5%) and 2014 (56.0%), but lower than in 2013 (67.4%). 1, 5, 7, 30 Levofloxacin resistance was detected in 4.1%-4.4% of BHS. Elevated rates of levofloxacin resistance were seen in APAC nations (10.3% overall), with the highest rates in Korea (17.4%) and Japan (47.4%).
JAC
The MIC 50 and MIC 90 results reported here agree with those published previously for the ZAAPS Program. 5, 7, 30 The results suggest sustained potency of linezolid over time, with no indication of MIC creep. A very limited number of surveyed isolates demonstrated decreased susceptibility to linezolid (4 mg/L) and, aside from a single isolate of S. aureus, that phenotype was only observed among enterococci and CoNS during 2015 and mainly recovered from Italian hospitals. The CoNS isolates contained alterations in the 23S rRNA and/or L3/L4 proteins, with one isolate also harbouring the cfr resistance gene. In addition, the newly described resistance mechanism, the optrA gene, was discovered in one E. faecalis isolate from Ireland. This gene was initially reported in E. faecalis and E. faecium of human and animal origin in China. 10 Moreover, follow-up studies have documented the detection of optrA in China (2010-14), Italy, England, Austria and the USA. 8, 18, 21, 23, 24 These data emphasize the importance of active surveillance for monitoring the emergence of resistance and details of genetic determinants. These results support the continued long-term and stable in vitro activity of this oxazolidinone (linezolid) against clinical Gram-positive pathogens causing infections worldwide. Pfaller et al.
